Antiphospholipid antibodies attenuate endothelial repair and promote neointima formation in mice

Journal of the American Heart Association

Volumn 3, Issue 5, 2014, Pages

  Ulrich, Victoria ^a   Konaniah, Eddy S ^b   Lee, Wan Ru ^a   Khadka, Sadiksha ^a   Shen, Yu Min ^a   Herz, Joachim ^a   Salmon, Jane E ^c   Hui, David Y ^b   Shaul, Philip W ^a   Mineo, Chieko ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Antiphospholipid syndrome; Endothelium; Neointima hyperplasia; Nitric oxide

Indexed keywords

APOLIPOPROTEIN E RECEPTOR 2; BETA2 GLYCOPROTEIN 1; LIPOPROTEIN RECEPTOR; NITRIC OXIDE; PHOSPHOLIPID ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; CELL MIGRATION; CELL PROLIFERATION; CELL REGENERATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENDOTHELIAL REPAIR; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; GROWTH INHIBITION; IN VIVO STUDY; MALE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; ANIMAL; ANTIPHOSPHOLIPID SYNDROME; C57BL MOUSE; CAROTID ARTERY INJURY; CELL CULTURE; CELL MOTION; CYTOLOGY; DISEASE MODEL; HYPERTROPHY; IMMUNOLOGY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZATION; SENSITIVITY AND SPECIFICITY; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BIOLOGICAL AVAILABILITY; CAROTID ARTERY INJURIES; CELL MOVEMENT; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HYPERTROPHY; MALE; MICE; MICE, INBRED C57BL; NEOINTIMA; NITRIC OXIDE; RANDOM ALLOCATION; SENSITIVITY AND SPECIFICITY;

EID: 84923859860     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.114.001369     Document Type: Article

References (67)

1. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002;346:752-763.
2. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, de Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
3. Soltesz P, Szekanecz Z, Kiss E, Shoenfeld Y. Cardiac manifestations in antiphospholipid syndrome. Autoimmun Rev. 2007;6:379-386.
4. Ames PR, Antinolfi I, Scenna G, Gaeta G, Margaglione M, Margarita A. Atherosclerosis in thrombotic primary antiphospholipid syndrome. J Thromb Haemost. 2009;7:537-542.
5. Der H, Kerekes G, Veres K, Szodoray P, Toth J, Lakos G, Szegedi G, Soltesz P. Impaired endothelial function and increased carotid intima-media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome. Lupus. 2007;16:497-503.
6. Ames PR, Margarita A, Sokoll KB, Weston M, Brancaccio V. Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis. 2005;64:315-317.
7. Ames PR, Margarita A, Delgado AJ, Tommasino C, Iannaccone L, Brancaccio V. Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus. 2002;11:208-214.
8. Medina G, Casaos D, Jara LJ, Vera-Lastra O, Fuentes M, Barile L, Salas M. Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann Rheum Dis. 2003;62:607-610.
9. Rosenthal E, Sangle SR, Taylor P, Khamashta MA, Hughes GR, D'Cruz DP. Treatment of mesenteric angina with prolonged anticoagulation in a patient with antiphospholipid (Hughes) syndrome and coeliac artery stenosis. Ann Rheum Dis. 2006;65:1398-1399.
10. Remondino GI, Mysler E, Pissano MN, Furattini MC, Basta MC, Presas JL, Allievi A. A reversible bilateral renal artery stenosis in association with antiphospholipid syndrome. Lupus. 2000;9:65-67.
11. Sangle SR, Jan W, Lau IS, Bennett AN, Hughes GR, D'Cruz DP. Coeliac artery stenosis and antiphospholipid (Hughes) syndrome/antiphospholipid antibodies. Clin Exp Rheumatol. 2006;24:349.
12. Sangle SR, D'Cruz DP, Jan W, Karim MY, Khamashta MA, Abbs IC, Hughes GR. Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension. Ann Rheum Dis. 2003;62:999-1002.
13. Sangle SR, D'Cruz DP. Renal artery stenosis: a new facet of the antiphospholipid (Hughes) syndrome. Lupus. 2003;12:803-804.
14. Sangle SR, D'Cruz DP, Abbs IC, Khamashta MA, Hughes GR. Renal artery stenosis in hypertensive patients with antiphospholipid (Hughes) syndrome: outcome following anticoagulation. Rheumatology (Oxford). 2005;44:372-377.
15. Peleg H, Bursztyn M, Hiller N, Hershcovici T. Renal artery stenosis with significant proteinuria may be reversed after nephrectomy or revascularization in patients with the antiphospholipid antibody syndrome: a case series and review of the literature. Rheumatol Int. 2012;32:85-90.
16. de Groot PG, Derksen RH. Pathophysiology of the antiphospholipid syndrome. J Thromb Haemost. 2005;3:1854-1860.
17. Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol. 2011;7:330-339.
18. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013;368:1033-1044.
19. de Laat B, de Groot PG. Autoantibodies directed against domain I of beta2-glycoprotein I. Curr Rheumatol Rep 2011;13:70-76.
20. Gushiken FC, Arnett FC, Thiagarajan P. Primary antiphospholipid antibody syndrome with mutations in the phospholipid binding domain of beta(2)-glycoprotein I. Am J Hematol. 2000;65:160-165.
21. Ramesh S, Morrell CN, Tarango C, Thomas GD, Yuhanna IS, Girardi G, Herz J, Urbanus RT, de Groot PG, Thorpe PE, Salmon JE, Shaul PW, Mineo C. Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via beta2GPI and apoER2. J Clin Invest. 2011;121:120-131.
22. Niimi Y, Azuma H, Hirakawa K. Repeated endothelial removal augments intimal thickening and attenuates EDRF release. Am J Physiol. 1994;266:H1348-H1356.
23. Cunningham KS, Gotlieb AI. The role of shear stress in the pathogenesis of atherosclerosis. Lab Invest. 2005;85:9-23.
24. Grote K, Sonnenschein K, Kapopara PR, Hillmer A, Grothusen C, Salguero G, Kotlarz D, Schuett H, Bavendiek U, Schieffer B. Toll-like receptor 2/6 agonist macrophage-activating lipopeptide-2 promotes reendothelialization and inhibits neointima formation after vascular injury. Arterioscler Thromb Vasc Biol. 2013;33:2097-2104.
25. Kipshidze N, Dangas G, Tsapenko M, Moses J, Leon MB, Kutryk M, Serruys P. Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. J Am Coll Cardiol. 2004;44:733-739.
26. Ma X, Hibbert B, Dhaliwal B, Seibert T, Chen YX, Zhao X, O'Brien ER. Delayed re-endothelialization with rapamycin-coated stents is rescued by the addition of a glycogen synthase kinase-3beta inhibitor. Cardiovasc Res. 2010;86:338-345.
27. Jones CI, Barrett NE, Moraes LA, Gibbins JM, Jackson DE. Endogenous inhibitory mechanisms and the regulation of platelet function. Methods Mol Biol. 2012;788:341-366.
28. Voetsch B, Jin RC, Loscalzo J. Nitric oxide insufficiency and atherothrombosis. Histochem Cell Biol. 2004;122:353-367.
29. Freedman JE. Oxidative stress and platelets. Arterioscler Thromb Vasc Biol. 2008;28:s11-s16.
30. Zhu B, Kuhel DG, Witte DP, Hui DY. Apolipoprotein E inhibits neointimal hyperplasia after arterial injury in mice. Am J Pathol. 2000;157:1839-1848.
31. He J, Luster TA, Thorpe PE. Radiation-enhanced vascular targeting of human lung cancers in mice with a monoclonal antibody that binds anionic phospholipids. Clin Cancer Res. 2007;13:5211-5218.
32. Schwartz R, Osborne-Lawrence S, Hahner L, Gibson LL, Gormley AK, Vongpatanasin W, Zhu W, Word RA, Seetharam D, Black S, Samols D, Mineo C, Shaul PW. C-reactive protein downregulates endothelial NO synthase and attenuates reendothelialization in vivo in mice. Circ Res. 2007;100:1452-1459.
33. Seetharam D, Mineo C, Gormley AK, Gibson LL, Vongpatanasin W, Chambliss KL, Hahner LD, Cummings ML, Kitchens RL, Marcel YL, Rader DJ, Shaul PW. High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ Res. 2006;98:63-72.
34. Hui DY. Intimal hyperplasia in murine models. Curr Drug Targets. 2008;9:251-260.
35. Gupta SK, Singh JP. Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression. J Cell Biol. 1994;127:1121-1127.
36. Basford JE, Moore ZW, Zhou L, Herz J, Hui DY. Smooth muscle LDL receptorrelated protein-1 inactivation reduces vascular reactivity and promotes injuryinduced neointima formation. Arterioscler Thromb Vasc Biol. 2009;29:1772-1778.
37. Urbanus RT, Derksen RH, de Groot PG. Platelets and the antiphospholipid syndrome. Lupus. 2008;17:888-894.
38. Vega-Ostertag ME, Pierangeli SS. Mechanisms of aPL-mediated thrombosis: effects of aPL on endothelium and platelets. Curr Rheumatol Rep. 2007;9:190-197.
39. Doran AC, Meller N, McNamara CA. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28:812-819.
40. Pierangeli SS, Vega-Ostertag ME, Raschi E, Liu X, Romay-Penabad Z, De Micheli V, Galli M, Moia M, Tincani A, Borghi MO, Nguyen-Oghalai T, Meroni PL. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis. 2007;66:1327-1333.
41. Cockrell E, Espinola RG, McCrae KR. Annexin A2: biology and relevance to the antiphospholipid syndrome. Lupus. 2008;17:943-951.
42. Romay-Penabad Z, guilar-Valenzuela R, Urbanus RT, Derksen RH, Pennings MT, Papalardo E, Shilagard T, Vargas G, Hwang Y, deGroot PG, Pierangeli SS. Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome. Blood 2011;117:1408-1414.
43. Kawasaki K, Smith RS Jr, Hsieh CM, Sun J, Chao J, Liao JK. Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol Cell Biol. 2003;23:5726-5737.
44. Michaelis UR, Fleming I. From endothelium-derived hyperpolarizing factor (EDHF) to angiogenesis: epoxyeicosatrienoic acids (EETs) and cell signaling. Pharmacol Ther. 2006;111:584-595.
45. Singh RJ, Hogg N, Joseph J, Konorev E, Kalyanaraman B. The peroxynitrite generator, SIN-1, becomes a nitric oxide donor in the presence of electron acceptors. Arch Biochem Biophys. 1999;361:331-339.
46. Charakida M, Besler C, Batuca JR, Sangle S, Marques S, Sousa M, Wang G, Tousoulis D, Delgado AJ, Loukogeorgakis SP, Kworth-Young C, D'Cruz D, Luscher T, Landmesser U, Deanfield JE. Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA 2009;302:1210-1217.
47. Belizna CC, Richard V, Primard E, Kerleau JM, Cailleux N, Louvel JP, Marie I, Hamidou M, Thuillez C, Levesque H. Early atheroma in primary and secondary antiphospholipid syndrome: an intrinsic finding. Semin Arthritis Rheum. 2008;37:373-380.
48. Taylor LM Jr, Chitwood RW, Dalman RL, Sexton G, Goodnight SH, Porter JM. Antiphospholipid antibodies in vascular surgery patients. A cross-sectional study. Ann Surg. 1994;220:544-550.
49. Lam EY, Taylor LM Jr, Landry GJ, Porter JM, Moneta GL. Relationship between antiphospholipid antibodies and progression of lower extremity arterial occlusive disease after lower extremity bypass operations. J Vasc Surg. 2001;33:976-982.
50. Long BR, Leya F. The role of antiphospholipid syndrome in cardiovascular disease. Hematol Oncol Clin North Am 2008;22:79-94.
51. Pierangeli SS, Vega-Ostertag M, Harris EN. Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies. Thromb Res. 2004;114:467-476.
52. Moroi M, Zhang L, Yasuda T, Virmani R, Gold HK, Fishman MC, Huang PL. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J Clin Invest. 1998;101:1225-1232.
53. Urbanus RT, Pennings MT, Derksen RH, de Groot PG. Platelet activation by dimeric beta2-glycoprotein I requires signaling via both glycoprotein Ibalpha and apolipoprotein E receptor 2'. J Thromb Haemost. 2008;6:1405-1412.
54. de Groot PG, vanLummel M, Pennings M, Urbanus R, Bas de Laat H, Lenting PJ, Derksen RH. Beta2-glycoprotein I and LDL-receptor family members. Thromb Res. 2004;114:455-459.
55. Ostertag MV, Liu X, Henderson V, Pierangeli SS. A peptide that mimics the Vth region of beta-2-glycoprotein I reverses antiphospholipid-mediated thrombosis in mice. Lupus. 2006;15:358-365.
56. Ioannou Y, Romay-Penabad Z, Pericleous C, Giles I, Papalardo E, Vargas G, Shilagard T, Latchman DS, Isenberg DA, Rahman A, Pierangeli S. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. J Thromb Haemost. 2009;7:833-842.
57. Blank M, Shoenfeld Y, Cabilly S, Heldman Y, Fridkin M, Katchalski-Katzir E. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci USA. 1999;96:5164-5168.
58. Asahara T, Isner JM. Endothelial progenitor cells for vascular regeneration. J Hematother Stem Cell Res. 2002;11:171-178.
59. Isner JM, Kalka C, Kawamoto A, Asahara T. Bone marrow as a source of endothelial cells for natural and iatrogenic vascular repair. Ann N Y Acad Sci. 2001;953:75-84.
60. Gresele P, Migliacci R, Vedovati MC, Ruffatti A, Becattini C, Facco M, Guglielmini G, Boscaro E, Mezzasoma AM, Momi S, Pengo V. Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. Thromb Res. 2009;123:444-451.
61. Meroni PL, Borghi MO, Raschi E, Ventura D, Sarzi PUTTINI PC, Atzeni F, Lonati L, Parati G, Tincani A, Mari D, Tedesco F. Inflammatory RESPONSE, the ENDOTHELIUM. Thromb Res. 2004;114:329-334.
62. Saxena A, Rauch U, Berg KE, Andersson L, Hollender L, Carlsson AM, Gomez MF, Hultgardh-Nilsson A, Nilsson J, Bjorkbacka H. The vascular repair process after injury of the carotid artery is regulated by IL-1RI and MyD88 signalling. Cardiovasc Res. 2011;91:350-357.
63. Simon DI. Inflammation and vascular injury: basic discovery to drug development. Circ J. 2012;76:1811-1818.
64. Breitenstein A, Camici GG, Tanner FC. Tissue factor: beyond coagulation in the cardiovascular system. Clin Sci (Lond). 2010;118:159-172.
65. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376:1498-1509.
66. Di Simone N, D'Ippolito S, Marana R, Di NF, Castellani R, Pierangeli SS, Chen P, Tersigni C, Scambia G, Meroni PL. Antiphospholipid antibodies affect human endometrial angiogenesis: protective effect of a synthetic peptide (TIFI) mimicking the phospholipid binding site of beta glycoprotein I. Am J Reprod Immunol. 2013;70:299-308.
67. Di Simone N, Di NF, D'Ippolito S, Castellani R, Tersigni C, Caruso A, Meroni P, Marana R. Antiphospholipid antibodies affect human endometrial angiogenesis. Biol Reprod. 2010;83:212-219.